MedCity News May 17, 2024
Amgen’s Imdelltra has FDA approval in extensive-stage small cell lung cancer, making it the first bispecific T cell engager approved for treating this type of cancer. Analysts project the new Amgen drug will become a blockbuster seller.
Small cell lung cancer typically responds to chemotherapy, but relapse of this aggressive type of cancer is common and the second-line treatment options offer limited benefit. FDA approval of a new Amgen drug gives patients another treatment option.
The drug, tarlatamab, is now approved to treat adults whose extensive-stage small cell lung cancer has progressed on or after treatment with platinum-based chemotherapy. The approval announced late Thursday came about a month ahead of the expected date for a regulatory decision. Amgen will market...
Today's Sponsors
Today's Sponsor